Johnson & Johnson (JNJ) Stock Forecast & Price Target

Compare

27,712 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

JNJ Analyst Ratings

Moderate Buy

9 Buy

4 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Johnson

& Johnson

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

JNJ Stock 12 Month Forecast

Average Price Target

$243.00

▲(5.31% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $243.00 with a high forecast of $265.00 and a low forecast of $217.00. The average price target represents a 5.31% change from the last price of $230.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"146":"$146","176":"$176","206":"$206","236":"$236","266":"$266"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":265,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$265.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":243,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$243.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":217,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$217.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[146,176,206,236,266],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,230.75,233.3846153846154,236.01923076923077,238.65384615384616,241.28846153846155,243.92307692307693,246.55769230769232,249.19230769230768,251.82692307692307,254.46153846153845,257.09615384615387,259.7307692307692,262.36538461538464,{"y":265,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,230.75,231.69230769230768,232.6346153846154,233.57692307692307,234.51923076923077,235.46153846153845,236.40384615384616,237.34615384615384,238.28846153846155,239.23076923076923,240.17307692307693,241.1153846153846,242.05769230769232,{"y":243,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,230.75,229.69230769230768,228.6346153846154,227.57692307692307,226.51923076923077,225.46153846153845,224.40384615384616,223.34615384615384,222.28846153846155,221.23076923076923,220.17307692307693,219.1153846153846,218.05769230769232,{"y":217,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":147.63,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.89,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.06,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.94,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.34,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":206.95,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":230.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$265.00

Average Price Target$243.00

Lowest Price Target$217.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Shagun Singh Chadha

RBC Capital

$240→$255

Buy

10.51%

Upside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), UnitedHealth (NYSE: UNH) and Johnson & Johnson (NYSE: JNJ)

Jason Gerberry

Bank of America Securities

$221→$227

Hold

-1.63%

Downside

Reiterated

01/30/26

Johnson & Johnson price target raised to $227 from $221 at BofAJohnson & Johnson price target raised to $227 from $221 at BofA

Terence Flynn

Morgan Stanley

$200→$262

Buy

13.54%

Upside

Upgraded

01/28/26

Johnson & Johnson upgraded to Overweight from Equal Weight at Morgan StanleyJohnson & Johnson upgraded to Overweight from Equal Weight at Morgan Stanley

Vamil Divan

Guggenheim

$227→$240

Buy

4.01%

Upside

Reiterated

01/23/26

Johnson & Johnson price target raised to $240 from $227 at GuggenheimJohnson & Johnson price target raised to $240 from $227 at Guggenheim

Matt Miksic

Barclays

$217

Hold

-5.96%

Downside

Reiterated

01/22/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Medtronic (NYSE: MDT), Outlook Therapeutics (NASDAQ: OTLK) and Johnson & Johnson (NYSE: JNJ)

Asad Haider

Goldman Sachs

$240→$250

Buy

8.34%

Upside

Reiterated

01/22/26

Johnson & Johnson price target raised to $250 from $240 at Goldman SachsJohnson & Johnson price target raised to $250 from $240 at Goldman Sachs

Joanne Wuensch

Citi

$232→$250

Buy

8.34%

Upside

Reiterated

01/22/26

Johnson & Johnson price target raised to $250 from $232 at CitiJohnson & Johnson price target raised to $250 from $232 at Citi

Josh Jennings

TD Cowen

$222→$250

Buy

8.34%

Upside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Johnson & Johnson (NYSE: JNJ)

Larry Biegelsen

Wells Fargo

$230→$240

Buy

4.01%

Upside

Reiterated

01/22/26

Johnson & Johnson price target raised to $240 from $230 at Wells FargoJohnson & Johnson price target raised to $240 from $230 at Wells Fargo

Louise Chen

Scotiabank

$230→$265

Buy

14.84%

Upside

Reiterated

01/22/26

Johnson & Johnson (JNJ) Gets a Buy from Scotiabank

Rick Wise

Stifel Nicolaus

$205→$220

Hold

-4.66%

Downside

Reiterated

01/22/26

Stifel Nicolaus Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

Lee Hambright

Bernstein

Hold

―

Reiterated

01/16/26

Bernstein Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)

Morten Herholdt

HSBC

$240

Buy

4.01%

Upside

Reiterated

01/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Risinger

Leerink Partners

$171→$201

Hold

-12.89%

Downside

Reiterated

10/16/25

Johnson & Johnson (JNJ) Gets a Hold from Leerink Partners

Jayson Bedford

Raymond James

$174→$209

Buy

-9.43%

Downside

Reiterated

10/15/25

Johnson & Johnson price target raised to $209 from $174 at Raymond JamesJohnson & Johnson price target raised to $209 from $174 at Raymond James

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Shagun Singh Chadha

RBC Capital

$240→$255

Buy

10.51%

Upside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), UnitedHealth (NYSE: UNH) and Johnson & Johnson (NYSE: JNJ)

Jason Gerberry

Bank of America Securities

$221→$227

Hold

-1.63%

Downside

Reiterated

01/30/26

Johnson & Johnson price target raised to $227 from $221 at BofAJohnson & Johnson price target raised to $227 from $221 at BofA

Terence Flynn

Morgan Stanley

$200→$262

Buy

13.54%

Upside

Upgraded

01/28/26

Johnson & Johnson upgraded to Overweight from Equal Weight at Morgan StanleyJohnson & Johnson upgraded to Overweight from Equal Weight at Morgan Stanley

Vamil Divan

Guggenheim

$227→$240

Buy

4.01%

Upside

Reiterated

01/23/26

Johnson & Johnson price target raised to $240 from $227 at GuggenheimJohnson & Johnson price target raised to $240 from $227 at Guggenheim

Matt Miksic

Barclays

$217

Hold

-5.96%

Downside

Reiterated

01/22/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Medtronic (NYSE: MDT), Outlook Therapeutics (NASDAQ: OTLK) and Johnson & Johnson (NYSE: JNJ)

Asad Haider

Goldman Sachs

$240→$250

Buy

8.34%

Upside

Reiterated

01/22/26

Johnson & Johnson price target raised to $250 from $240 at Goldman SachsJohnson & Johnson price target raised to $250 from $240 at Goldman Sachs

Joanne Wuensch

Citi

$232→$250

Buy

8.34%

Upside

Reiterated

01/22/26

Johnson & Johnson price target raised to $250 from $232 at CitiJohnson & Johnson price target raised to $250 from $232 at Citi

Josh Jennings

TD Cowen

$222→$250

Buy

8.34%

Upside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Johnson & Johnson (NYSE: JNJ)

Larry Biegelsen

Wells Fargo

$230→$240

Buy

4.01%

Upside

Reiterated

01/22/26

Johnson & Johnson price target raised to $240 from $230 at Wells FargoJohnson & Johnson price target raised to $240 from $230 at Wells Fargo

Louise Chen

Scotiabank

$230→$265

Buy

14.84%

Upside

Reiterated

01/22/26

Johnson & Johnson (JNJ) Gets a Buy from Scotiabank

Rick Wise

Stifel Nicolaus

$205→$220

Hold

-4.66%

Downside

Reiterated

01/22/26

Stifel Nicolaus Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

Lee Hambright

Bernstein

Hold

―

Reiterated

01/16/26

Bernstein Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)

Morten Herholdt

HSBC

$240

Buy

4.01%

Upside

Reiterated

01/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Risinger

Leerink Partners

$171→$201

Hold

-12.89%

Downside

Reiterated

10/16/25

Johnson & Johnson (JNJ) Gets a Hold from Leerink Partners

Jayson Bedford

Raymond James

$174→$209

Buy

-9.43%

Downside

Reiterated

10/15/25

Johnson & Johnson price target raised to $209 from $174 at Raymond JamesJohnson & Johnson price target raised to $209 from $174 at Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Johnson & Johnson

3 Months

xxx

Success Rate

23/26 ratings generated profit

Average Return

+4.86%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 88.46% of your transactions generating a profit, with an average return of +4.86% per trade.

1 Year

Danielle AntalffyUBS

Success Rate

26/26 ratings generated profit

Average Return

+11.45%

reiterated a buy rating 4 months ago

Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +11.45% per trade.

2 Years

xxx

Success Rate

23/24 ratings generated profit

Average Return

+33.52%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.83% of your transactions generating a profit, with an average return of +33.52% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JNJ Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, JNJ has received 24 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. JNJ average Analyst price target in the past 3 months is 243.00.

Each month's total comprises the sum of three months' worth of ratings.

JNJ Financial Forecast

JNJ Earnings Forecast

Next quarter’s earnings estimate for JNJ is $2.69 with a range of $2.14 to $2.90. The previous quarter’s EPS was $2.46. JNJ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.

JNJ Sales Forecast

Next quarter’s sales forecast for JNJ is $23.60B with a range of $22.41B to $24.23B. The previous quarter’s sales results were $24.56B. JNJ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.

JNJ Stock Forecast FAQ

What is JNJ’s average 12-month price target, according to analysts?

Based on analyst ratings, Johnson & Johnson’s 12-month average price target is 243.00.

What is JNJ’s upside potential, based on the analysts’ average price target?

Johnson & Johnson has 5.31% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is JNJ a Buy, Sell or Hold?

Johnson & Johnson has a consensus rating of Moderate Buy which is based on 9 buy ratings, 4 hold ratings and 0 sell ratings.

What is Johnson & Johnson’s price target?

The average price target for Johnson & Johnson is 243.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $265.00 ,the lowest forecast is $217.00. The average price target represents 5.31% Increase from the current price of $230.75.

What do analysts say about Johnson & Johnson?

Johnson & Johnson’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of JNJ?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Johnson & Johnson (JNJ) Stock Forecast & Price Target

JNJ Analyst Ratings

JNJ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Johnson & Johnson

JNJ Analyst Recommendation Trends

JNJ Financial Forecast

JNJ Earnings Forecast

JNJ Sales Forecast

JNJ Stock Forecast FAQ

Detailed List of Analyst Forecasts